

1 **Delayed viral clearance and exacerbated airway hyperinflammation in**
2 **hypertensive COVID-19 patients**

3
4 Saskia Trump^{1#}, Soeren Lukassen^{2#}, Markus S. Anker^{3#}, Robert Lorenz Chua^{2#},
5 Johannes Liebig^{2#}, Loreen Thürmann^{1#}, Victor Corman⁴, Marco Binder⁵, Jennifer
6 Loske¹, Christina Klasa⁶, Teresa Krieger², Bianca P. Hennig², Marey
7 Messingschlager¹, Fabian Pott^{4,7}, Julia Kazmierski^{4,7}, Sven Twardziok², Jan Philipp
8 Albrecht², Jürgen Eils², Sara Hadzibegovic³, Alessia Lena³, Bettina Heidecker³,
9 Christine Goffinet^{4,7}, Florian Kurth^{8,9}, Martin Witzenrath⁸, Maria Theresa Völker¹⁰,
10 Sarah Dorothea Müller¹⁰, Uwe Gerd Liebert¹¹, Naveed Ishaque², Lars Kaderali⁶, Leif-
11 Erik Sander⁸, Sven Laudi¹⁰, Christian Drosten⁴, Roland Eils^{2,12,13*}, Christian Conrad^{2*},
12 Ulf Landmesser^{14*}, Irina Lehmann^{1,12*}

13
14 Affiliation

15 ¹ Molecular Epidemiology Unit, Charité - Universitätsmedizin Berlin, corporate member of Freie
16 Universität Berlin, Humboldt-Universität zu Berlin, and Berlin Institute of Health (BIH), Berlin, Germany

17 ² Center for Digital Health, Berlin Institute of Health (BIH) and Charité - Universitätsmedizin Berlin,
18 corporate member of Freie Universität Berlin, Humboldt-Universität zu Berlin, Berlin, Germany

19 ³ Division of Cardiology and Metabolism (CVK) and Department of Cardiology (CBF), Charité
20 Universitätsmedizin Berlin; Berlin Institute of Health Center for Regenerative Therapies (BCRT) and
21 Centre for Cardiovascular Research (DZHK) partner site Berlin, Berlin, Germany

22 ⁴ Institute of Virology, Charité - Universitätsmedizin Berlin, corporate member of Freie Universität Berlin,
23 Humboldt-Universität zu Berlin, and Berlin Institute of Health (BIH), Berlin, Germany

24 ⁵ Research group "Dynamics of early viral infection and the innate antiviral response" (division F170),
25 German Cancer Research Center (DKFZ), Heidelberg, Berlin

26 ⁶ Institute for Bioinformatics, University Medicine Greifswald, Greifswald, Germany

27 ⁷ Berlin Institute of Health (BIH), Berlin, Germany

NOTE: This preprint reports new research that has not been certified by peer review and should not be used to guide clinical practice.

1 ⁸ Department of Infectious Diseases and Respiratory Medicine, Charité - Universitätsmedizin Berlin,
2 corporate member of Freie Universität Berlin, Humboldt-Universität zu Berlin, and Berlin Institute of
3 Health (BIH), Berlin, Germany

4 ⁹ Department of Tropical Medicine, Bernhard Nocht Institute for Tropical Medicine & I. Department of
5 Medicine, University Medical Center Hamburg-Eppendorf, Hamburg, Germany

6 ¹⁰ Department of Anesthesiology and Intensive Care, University Hospital Leipzig, Leipzig, Germany

7 ¹¹ Institute of Virology, University Hospital Leipzig, Leipzig, Germany

8 ¹² German Center for Lung Research (DZL), Germany

9 ¹³ Health Data Science Unit, Heidelberg University Hospital and BioQuant, Heidelberg, Germany

10 ¹⁴ Department of Cardiology, Charité - Universitätsmedizin Berlin, corporate member of Freie Universität
11 Berlin, Humboldt-Universität zu Berlin, and Berlin Institute of Health (BIH), Berlin, Germany

12

13

14 #shared first author

15 *shared senior author/corresponding author

16

17

1 **Abstract**

2

3 In COVID-19, hypertension and cardiovascular diseases have emerged as major risk
4 factors for critical disease progression. Concurrently, the impact of the main anti-
5 hypertensive therapies, angiotensin-converting enzyme inhibitors (ACEi) and
6 angiotensin receptor blockers (ARB), on COVID-19 severity is controversially
7 discussed. By combining clinical data, single-cell sequencing data of airway samples
8 and *in vitro* experiments, we assessed the cellular and pathophysiological changes in
9 COVID-19 driven by cardiovascular disease and its treatment options. Anti-
10 hypertensive ACEi or ARB therapy, was not associated with an altered expression of
11 SARS-CoV-2 entry receptor *ACE2* in nasopharyngeal epithelial cells and thus
12 presumably does not change susceptibility for SARS-CoV-2 infection. However, we
13 observed a more critical progress in COVID-19 patients with hypertension associated
14 with a distinct inflammatory predisposition of immune cells. While ACEi treatment was
15 associated with dampened COVID-19-related hyperinflammation and intrinsic anti-viral
16 responses, under ARB treatment enhanced epithelial-immune cell interactions were
17 observed. Macrophages and neutrophils of COVID-19 patients with hypertension and
18 cardiovascular comorbidities, in particular under ARB treatment, exhibited higher
19 expression of *CCL3*, *CCL4*, and its receptor *CCR1*, which associated with critical
20 COVID-19 progression. Overall, these results provide a potential explanation for the
21 adverse COVID-19 course in patients with cardiovascular disease, i.e. an augmented
22 immune response in critical cells for the disease course, and might suggest a beneficial
23 effect of clinical ACEi treatment in hypertensive COVID-19 patients.

24

25

26

1 Introduction

2 The ongoing coronavirus disease 2019 (COVID-19) pandemic is caused by the severe
3 acute respiratory syndrome coronavirus 2 (SARS-CoV-2). Among patients hospitalized
4 for COVID-19 males and those of older age emerged as having a higher risk for critical
5 COVID-19^{1, 2}. Hypertension, highly prevalent in adults worldwide³, has been identified
6 as a major risk factor for COVID-19 severity^{4, 5}. Hypertensive COVID-19 patients are
7 more likely to develop severe pneumonia or organ damage than non-hypertensive
8 patients. In addition, these patients exhibit exacerbated inflammatory responses and
9 have a higher risk of dying from COVID-19 than non-hypertensive patients^{4, 6}.

10 SARS-CoV-2 exploits the ACE2 receptor, expressed on epithelial cells in the
11 respiratory system, for cellular attachment and entry⁷. ACE2 is a membrane-bound
12 aminopeptidase and is part of the non-canonical arm of the renin-angiotensin-
13 aldosterone system (RAAS), which regulates blood pressure homeostasis and
14 vascular repair responses. It has been speculated that antihypertensive treatment by
15 angiotensin-converting enzyme inhibitors (ACEi) or angiotensin receptor blockers
16 (ARBs) might modulate ACE2 expression and thereby alter susceptibility for SARS-
17 CoV-2 infection. In the classical RAAS pathway, angiotensin II binds to the
18 angiotensin-II-receptor-subtyp-1 (AT1R), which promotes vasoconstriction and pro-
19 inflammation. ACE2, on the other hand, cleaves angiotensin II into angiotensin 1-7,
20 which mediates vasodilatory and anti-inflammatory effects^{8, 9}.

21 Data from animal studies demonstrated that ACEi and ARB can up-regulate ACE2
22 expression¹⁰. This raised intense discussions on a potential increase in availability of
23 SARS-CoV-2 receptors in ACEi or ARB treated patients^{11, 12}, rendering them
24 potentially more susceptibility to viral infection and spread. To date there is no
25 evidence from observational studies that ACEi- or ARB-treatment could increase the
26 infectivity for SARS-CoV-2^{5, 13}.

1 Hypertension is associated with the activation of inflammatory processes^{14, 15}. As a
2 hyperinflammatory phenotype in the respiratory system has been described to
3 enhance severity of COVID-19^{16, 17}, we assessed whether a potential pro-inflammatory
4 predisposition of hypertensive patients before SARS-CoV-2 infection may contribute
5 to an exacerbated disease severity.

6 To this end we evaluated the impact of coexisting cardiovascular illnesses, in particular
7 of hypertension and anti-hypertensive treatment, on COVID-19 pathology and viral
8 clearance based on two German prospective cohorts. By analyzing the single-cell
9 transcriptome landscape of the airways of COVID-19 patients and SARS-CoV-2
10 negative controls we provide insights into the differential COVID-19 pathology in
11 ACEi/ARB-treated patients compared to those without cardiovascular diseases or
12 different anti-hypertensive treatment.

13

14 **Results**

15 **ACEi/ARB treatment was associated with a lower hypertension-related risk for** 16 **critical COVID-19**

17 We first assessed the impact of hypertension (HT+) and other cardiovascular diseases
18 (CVD+) with anti-hypertensive treatment on COVID-19 severity (Figure 1a). Both
19 medical conditions have been associated with a worse outcome in COVID-19^{5, 11-13, 18-}
20 ²⁰. Accordingly, we compared the proportion of critical cases to all other severities of
21 COVID-19 in the different patient groups of the Pa-COVID-19 cohort²¹ (see
22 Supplementary Table 1 for clinical characteristics). The proportion of patients with a
23 critical outcome was significantly increased for HT+/CVD± patients (n=90) compared
24 to HT-/CVD- COVID-19 patients (n=54, p-value=0.007). For HT+ patients, the risk for
25 critical COVID-19 was highest without ACEi- or ARB-treatment (see Supplementary
26 Table 2): almost 75% of HT+/CDV-patients and about two thirds of HT+/CVD+ patients

1 showed critical COVID-19. In contrast, ACEi- and ARB-treatment were associated with
2 a decreased proportion of critical COVID-19 in both groups (HT+/CVD- and
3 HT+CVD+), but ACEi treatment showed a more profound difference as compared to
4 ARB treatment. ACEi treated HT+/CVD± patients showed almost the same risk for
5 critical COVID-19 as HT-/CVD- patients (Supplementary Table 2).

6 To exclude the impact of other risk factors for an adverse COVID-19 clinical course,
7 we performed logistic regression analyses adjusted for known confounding factors
8 such as age, sex, and BMI. This analysis confirmed a higher risk for developing critical
9 COVID-19 for HT+/CVD- over HT-/CVD- (adjOR=2.38, 95%CI:1.09-5.21, p-
10 value=0.028). Even after adjustment for confounders ARB-treatment showed an
11 increased risk for critical COVID-19 (HT+/CVD- /ARB+, adjOR=3.85, 95%CI:1.01-
12 14.68, p-value=0.044), which was lower than for HT+/CVD- patients without ACEi or
13 ARB treatment (adjOR=4.94, 95%CI:1.46-16.79, p-value=0.009). The logistic
14 regression analysis revealed no significant increase for critical COVID-19 by ACEi
15 treatment compared to HT-/CVD-.

16 Our results showed that patients with hypertensive disease had an increased risk for
17 critical COVID-19. This risk was decreased by ACEi/ARB treatment. ACEi treatment
18 almost entirely abolished the additional risk, whereas ARB treatment only reduced the
19 hypertension-associated risk.

20

21 **ARB but not ACEi treatment was associated with delayed SARS-CoV-2 clearance**

22 We investigated the dynamics of SARS-CoV-2 clearance in patients included in the
23 Pa-COVID-19 cohort. During hospitalization, COVID-19 patients were tested
24 longitudinally for SARS-CoV-2 by qPCR of the viral genome. Using an adjusted
25 repeated measurement mixed model, we studied the changes of the viral load over
26 time, comparing ACEi+ (n=21) or ARB+ (n=26) COVID-19 patients with HT-/CVD-

1 COVID-19 patients (n=46). All three groups showed the same initial viral load while
2 ACEi+ treatment did not change viral clearance up to 16 days after the first positive
3 test compared to HT-/CVD-, ARB-treatment was associated with a significantly slower
4 viral clearance over time compared to HT-/CVD- (p-value=0.031) or ACEi+ (p-value=
5 0.026, Figure 1b), respectively. This finding was supported by the time-dependent
6 slope of viral load between the different patient groups. ARB+ patients tended to have
7 a flatter slope compared to HT-/CVD- (p-value=0.07, Extended Data Figure 1a). The
8 same was observed for HT+/ CVD± patients who showed a tendency of slower viral
9 clearance compared to HT-/CVD- patients (p-value=0.08, Extended Data Figure 1b).
10 Taken together, we showed that viral clearance in HT+/CVD± patients under ACEi
11 treatment was similar to that in COVID-19 patients without a coexisting cardiovascular
12 disease, while viral clearance may have been delayed in patients undergoing
13 hypertensive ARB treatment.

14

15 **Cardiovascular disease and SARS-CoV-2 infection affect cell type distribution**

16 To investigate the cellular and molecular impact of cardiovascular co-morbidities and
17 anti-hypertensive treatment on COVID-19 severity, we performed extensive single-cell
18 transcriptome profiling of nasopharyngeal samples from COVID-19 patients with or
19 without hypertension and other cardiovascular diseases (see Supplementary Table 3
20 for clinical characteristics). To disentangle the effect of HT and CVD on SARS-CoV-2
21 infection, we studied a mirror cohort of SARS-CoV-2 negative patients with and without
22 HT/CVD under ARB/ACEi treatment (Figure 2a). In total, we assessed the
23 transcriptomes of 114,761 individual cells obtained from nasopharyngeal swabs of 32
24 COVID-19 patients (n=25 with HT+/CVD±; n=10 ACEi+ and n=15 ARB+) and 16
25 SARS-CoV-2-negative controls (n=10 with HT+/CVD±; n=6 ACEi+ and n=4 ARB+).

1 Only individuals diagnosed with severe to critical COVID-19 or SARS-CoV-2-negative
2 controls were eligible for inclusion in this part of the study (Supplementary Table 3).
3 We identified nine immune and 12 epithelial cell populations (Figure 2b, Extended Data
4 Figure 2 and 3). While the relative abundance of the individual epithelial cell types
5 seemed largely unchanged (Extended Data Figure 3b) the immune cell population
6 upon infection was characterized by a massive increase of neutrophils (Neu, p-value
7 $< 2.66e-10$) and resident macrophages (rMa, p-value $< 5.78e-11$, Figure 2c) upon
8 infection. In HT+/CVD \pm COVID-19 patients, non-resident macrophages (nrMa, p-value
9 $< 2.10e-14$) and monocyte-derived macrophages (moMa, p-value $< 4.83e-10$) were
10 expanded compared to HT-/CVD- patients, independent of their anti-hypertensive
11 treatment (Figure 2c, Extended Data Figure 3b).

12

13 **Anti-hypertensive treatment is not associated with altered expression of the** 14 **SARS-CoV-2 entry receptor *ACE2***

15 SARS-CoV-2 enters the human cell via the receptor *ACE2* and with the help of the
16 protease *TMPRSS2*. It has been speculated that ARB and ACEi as RAAS-modulating
17 agents might change *ACE2* expression and thereby the infectivity for SARS-CoV-2.
18 Since the expression of *ACE2* is generally low in human airways²², we quantified total
19 *ACE2* expression per sample. In line with previous studies^{23, 24}, we found an overall
20 increased expression of both *ACE2* (p=0.0025, Extended Data Figure 4a) and
21 *TMPRSS2* (p-value= 0.0002, Extended Data Figure 4b) upon SARS-CoV-2 infection.
22 However, anti-hypertensive treatment did not alter *ACE2* expression, neither in SARS-
23 CoV-2-positive nor -negative patients.
24 We conclude that entry factor expression did not predispose ACEi or ARB treated
25 patients to SARS-CoV-2 infection. This finding is in accordance with observational

1 studies, which did not reveal any effect of ACEi or ARB treatment on SARS-CoV-2
2 infection risk in individuals with hypertension or other CVDs⁵.

3

4 **ARB-treated COVID-19 patients have a reduced cell-intrinsic anti-viral response**

5 We next assessed potential molecular mechanisms that may be involved in the
6 delayed viral clearance of ARB-treated patients within the Pa-COVID-19 cohort
7 described above. Pathway enrichment analysis based on the top 100 genes that were
8 significantly differentially expressed (log fold-change > 0.25, FDR < 0.05, expression
9 in > 10% of cells in one group) in either of the anti-hypertensive treatment groups
10 compared to the HT-/CVD- group showed an activation of genes involved in stress and
11 inflammatory response and antigen processing in ciliated cells of ARB+/HT+/CVD±
12 COVID-19 patients (Figure 3a, Extended Data Figure 5a, Supplementary Table 4). For
13 ACEi+/HT+/CVD± COVID-19 patients' pathways related to defense response and
14 regulation of viral genome replication were enriched in ciliated cells. Among those
15 genes involved in regulation of viral genome replication, we found a number of
16 statistically significantly upregulated type I interferon (IFN)-induced genes (e.g., *IFI6*,
17 *IFI27*, *ISG15*; Figure 3a-b) in both treatment groups.

18 In secretory cells, ACEi treatment resulted in upregulation of genes negatively
19 regulating immune system response to virus. Interestingly, ARB treatment led to a
20 strong induction of genes involved in chemotaxis and inflammatory response in
21 secretory cells (Figure 3a, Extended Data Figure 5a, Supplementary Table 4),
22 including *CXCL1*, *CXCL6*, and *IL-8*, which recruit and activate neutrophils, and
23 *CXCL17* which is a chemoattractant for monocytes, macrophages and dendritic cells
24 (Figure 3a,c).

25 Next, we sought to disentangle cell-intrinsic responses triggered by viral infection and
26 cell-extrinsic responses induced by signaling through type I/III IFNs. In an *in vitro*

1 setting using A549 cells, we studied the extrinsic and intrinsic transcriptional response
2 supposedly induced by SARS-CoV-2 infection. Cells were stimulated by either a highly
3 specific RIG-I ligand triggering prototypical antiviral signaling through IRF3 or by a
4 combination of IFN β and INF λ inducing prototypical IFN signaling through ISGF3
5 (Figure 3d). Although the major pattern recognition receptor for SARS-CoV-2 remains
6 elusive, all potential antiviral pathways converged on the transcription factors
7 IRF3/IRF7 and NF κ B²⁵, eliciting a similar transcriptional response (Supplementary
8 Table 4).

9 By overlapping the specific intrinsic and extrinsic antiviral response gene sets identified
10 in the *in vitro* experiment with the differentially expressed genes in secretory and
11 ciliated cells of COVID-19 patients (for enrichment see Methods), we observed that
12 overall ACEi but not ARB treatment was associated with a strong cell intrinsic anti-viral
13 response in SARS-CoV-2 positive patients (Figure 3e-f). Of note, already in SARS-
14 CoV-2-negative patients, anti-hypertensive treatment by ACEi/ARB led to the induction
15 of genes involved in the cell-intrinsic antiviral response in secretory but not in ciliated
16 cells (Figure 3e-f). In secretory cells, pre-activation of the intrinsic antiviral response
17 was further enhanced by ACEi-treatment of HT+/CVD \pm COVID-19 patients (Figure 3e).
18 Surprisingly, intrinsic viral response was abolished in ARB+ treated HT+/CVD \pm
19 COVID-19 patients. Extrinsic antiviral response genes were not pre-activated in SARS-
20 CoV-2-negative patients treated by ACEi or ARBs. Upon SARS-CoV-2 infection, a
21 robust extrinsic antiviral response was induced in both ciliated and secretory cells of
22 HT+/CVD \pm COVID-19 patients treated by ACEi or ARBs (Figure 3e-f). A transcription
23 factor binding motif analysis for genes differentially regulated in secretory cells
24 confirmed the notion that the classical cell-intrinsic antiviral signaling through
25 transcription factors such as IRF3, IRF1, and ISGF3 (ISRE) was enriched in ACEi+
26 treated HT+/CVD \pm COVID-19 patients (Extended Data Figure 5b). Instead, ARB+

1 treated patients showed a strong bias towards genes controlled by NF κ B, a hallmark
2 transcription factor for inflammatory conditions²⁶⁻²⁸.

3 Taken together, we observed a distinct difference in the balance between cell-intrinsic
4 and extrinsic antiviral responses of ARB vs. ACEi treatment of HT+/CVD \pm COVID-19
5 patients. The identified dampened intrinsic antiviral response in secretory and ciliated
6 cells of ARB-treated HT+/CVD \pm COVID-19 patients may have contributed to the above
7 described delay in SARS-CoV-2 clearance in those patients.

8

9 **Crosstalk between epithelial and immune cells is associated with anti-** 10 **hypertensive treatment in COVID-19 patients**

11 The above described differential gene expression by ACEi/ARB revealed a distinct
12 induction of inflammatory and chemoattractant genes. Hence, we inferred all possible
13 intercellular interactions of all cell types and states across the different conditions using
14 CellPhoneDB²⁹ (Figure 4). Basal, secretory, ciliated, non-resident macrophages
15 (nrMa), resident macrophages (rMa), neutrophils (Neu), and cytotoxic T cells (CTLs)
16 had the highest number of interactions within the nasopharyngeal mucosa of COVID-
17 19 patients (Figure 4a-b). A pre-existing cardiovascular comorbidity correlated with an
18 increased number of cell-cell interactions with most of the previously mentioned cell
19 types, gaining about 500 additional interactions upon SARS-CoV-2 infection (Figure
20 4a, Extended Data Figure 6a).

21 In SARS-CoV-2 negative patients, interactions in ACEi+ and ARB+ were very similar
22 in number and type (Extended Data Figure 6a-b). In contrast, for COVID-19 patients,
23 ACEi treatment was concomitant with a reduction of interactions, while interactions in
24 ARB treatment remained almost unchanged compared to HT+/CVD \pm patients.

25 The cell specific interactions were then categorized as intra- vs. inter-compartment
26 interactions (immune:immune and epithelial:epithelial vs. immune:epithelial

1 compartment interactions (Extended Data Figure 6c). In general, regardless of SARS-
2 CoV-2 infection status, epithelial cells exhibited more potential interactions with
3 themselves while immune cells had more inter-compartment interactions with epithelial
4 cells. When comparing interactions in SARS-CoV-2-negative and -positive patients,
5 we generally observed a loss of intra-compartment interactions for epithelial cells and
6 a gain in inter-compartment interactions with immune cells among all conditions. Both
7 inter- and intra-compartment interactions of immune cells tended to be increased in
8 HT+/CVD± compared to HT-/CVD- COVID-19 patients (Extended Data Figure 6c,
9 Supplementary Table 5). Accordingly, intra-compartment interactions upon SARS-
10 CoV-2 infection were exclusively statistically significantly increased in immune cell
11 types, but decreased in epithelial cells (Supplementary Table 5).

12 Notably, this finding was mostly impacted by ARB-treated patients showing an overall
13 increase in immune cell interactions, while ACEi-treated patients were similar to HT-
14 /CVD- COVID-19 patients (Extended Data Figure 6c; Supplementary Table 5). In
15 particular chemokine/chemokine receptor interactions mediated by nrMa (Figure 4c)
16 reflected the similarity between HT-/CVD- patients and ACEi-treated COVID-19
17 patients. HT+/CVD+ and ARB-treated COVID-19 patients were similar in their
18 interaction pattern, while in ACEi+ there was a reduced enrichment of interactions
19 between *CCL3/CCL4* and *CCR5*, and between *CCR5* and *CCL7*, respectively (Figure
20 4c). In line with the pronounced chemokine/chemokine receptor interaction, the
21 expression of *CCL2*, *CCL3*, *CCL4*, *CCL7*, and *CCL18* was upregulated in ARB+
22 concomitant with the expression of their receptors, e.g., *CCR1*, *CCR2*, and *CCR5*,
23 suggesting a higher interactivity of nrMa under ARB compared to ACEi treatment
24 (Extended Data Figure 6d).

25

1 **Hypertension-related inflammatory priming of immune cells is less pronounced** 2 **in ACEi treated patients**

3 To elucidate the deleterious contribution of hypertension on COVID-19, we evaluated
4 the transcriptional profile of the key immune cell types orchestrating the antiviral
5 response, namely T-cells, macrophages, and neutrophils. We and others showed that
6 macrophages, in particular nrMa, are key mediators of hyperinflammation in severe
7 COVID-19. High expression of genes coding for immune cell-recruiting chemokines,
8 such as *CCL2*, *CCL3* and *CCL4*, and inflammatory cytokines including
9 *IL1B* and *IL8*, are hallmarks of nrMa in COVID-19^{16, 17}. Upon SARS-CoV-2 infection,
10 HT+/CVD± patients showed a significantly increased expression of these inflammatory
11 mediators not only in macrophages but also in Neu compared to HT-/CVD- patients
12 (Figure 5a, Extended Data Figure 7a). This hyperinflammatory phenotype was not only
13 present in the upper airways but also in bronchial lavage (BL), as reflected by a
14 stronger activation of BL-nrMa and BL-Neu of a hypertensive COVID-19 patient (BIH-
15 SCV2-30) compared to a HT-/CVD- patient (BIH-SCV2-25, Extended Data Figure 7c).
16 Anti-hypertensive treatment by ACEi apparently decreased hypertension-related
17 hyperinflammation of COVID-19, while ARB was less effective in this regard (Figure
18 5a-c, Extended Data Figure 7b). In all macrophage subtypes, *CCL3* and *CCL4*
19 expression among others was elevated in HT+/CVD±/ARB+ compared to HT+/
20 CVD±/ACEi+. In line, Neu showed a pro-inflammatory characteristic (*IL8*, *CXCL2*) and
21 infiltrative potential (*ITGAM*, *ICAM1*) in ARB+ and to a much lesser extent in ACEi+,
22 when compared to HT-/CVD- patients (Figure 5c).
23 Notably, in the absence of SARS-CoV-2 infection HT+/CVD- and HT+/CVD+ were
24 characterized by inflammatory priming predominantly in nrMA and Neu (Figure 5a left
25 panel, Figure 5c) - but not in rMa (Extended Data Figure 7b). In contrast to what we
26 observed in COVID-19 patients, SARS-CoV-2-negative patients (HT+/CVD±/ACEi+

1 and HT+/ CVD±/ARB+) showed a similar chemokine fingerprint as reflected by an
2 increased expression of e.g. *CCL3* and *CCL4* (Figure 5a right panel, Figure 5c).

3 In agreement with the previously observed aggravated cytotoxic capacity of CTLs in
4 critical COVID-19 patients¹⁶, hypertensive patients treated with ARB or ACEi
5 expressed cytotoxic mediators like *PRF1* or *GZMK* to a larger extend than HT-/CVD-
6 patients upon infection with SARS-CoV-2 (Figure 5d). As expected, in the absence of
7 SARS-CoV-2 infection, CTLs were not activated and no apparent difference between
8 HT+/CVD±/ACEi+ or HT+/CVD±/ARB+ and HT-/CVD- patients was observed (Figure
9 5d).

10 In contrast, in NKT cells cytotoxic markers (e.g. *KLRD1*, *GZMB*) in addition to
11 monocyte-attractants (e.g. *CCL3*, *CCL4*) were already significantly elevated in SARS-
12 CoV-2 negative hypertensive patients (Extended Data Figure 7a) independent of the
13 type of anti-hypertensive treatment (Figure 5d). Upon infection, only in the ARB+ group
14 apoptotic mediators (e.g. *GZMB*) and different chemokines (e.g. *CCL3*, *CCL4*) were
15 significantly increased compared to HT-/CVD-.

16 Overall, we observed an increased expression of genes coding for pro-inflammatory
17 and cytotoxic mediators in immune cells of hypertensive patients, already present
18 before infection. ACEi but not ARB treatment apparently alleviated the hypertension-
19 related inflammatory response to SARS-CoV-2 infection.

20

21 **Exacerbated expression of *CCL3* and *CCL4* observed in ARB-treated** 22 **hypertensive patients correlates with disease severity**

23 We next evaluated whether the hypertension-related inflammatory predisposition of
24 nrMa, and Neu might contribute to an increased risk for critical COVID-19. *CCL3* and
25 *CCL4* in nrMa and Neu, which were induced in HT+/CVD+/- compared to HT-/CVD-
26 (Figure 5a-c), were statistically significantly elevated with the highest fold change in

1 critical COVID-19 patients (n= 23 severe vs. 9 critical, cut-off: average fold change
2 ≥ 0.25 , and $p\text{-value} \leq 0.05$, Figure 5e). Using a logistic regression model considering
3 age, gender, days post onset of symptoms and study center as potential confounding
4 factors we confirmed a significant relationship between increased expression of *CCL4*
5 derived from either nrMa (adj.OR/95% CI=1.04/1.00-1.07, $p\text{-value}=0.027$) or Neu
6 (adj.OR/95% CI=1.06/1.00-1.12, $p\text{-value}=0.044$) and *CCL3* expressed by Neu
7 (adj.OR/95% CI=1.13/1.01-1.27, $p\text{-value}=0.02$) and an increased risk for critical
8 COVID-19. Notably, expression of *CCR1*, the receptor bound by *CCL3* and *CCL4*,
9 increased in nrMa and Neu with COVID-19 severity supporting the potential of *CCR1*
10 as a therapeutic target¹⁶ (Extended Data Figure 7d). Antihypertensive treatment
11 increased *CCL3* and *CCL4* expression in immune cells of SARS-CoV-2 negative
12 patients, but in COVID-19 only ARB-treatment significantly elevated *CCL3/CCL4*
13 expression compared to HT-/CVD- COVID-19 (Figure 5f).
14 In summary, we could show that treatment with ACEi resulted in a more favorable
15 immune response after SARS-CoV-2 infection, while ARB therapy did not sufficiently
16 alleviate the hypertension-related hyperinflammation especially in nrMa and Neu,
17 possibly contributing to critical COVID-19 course (Figure 5g).

18
19

20 **Discussion**

21 This study identified potential novel molecular mechanisms underlying the finding from
22 observational studies that COVID-19 patients with hypertension or coronary artery
23 disease revealed higher morbidity and mortality rates^{4, 30, 31}. As first line anti-
24 hypertensive medication includes modulators of RAAS interfering with the pathway
25 employed by SARS-CoV-2 for cellular entry it has been debated whether ACEi or ARB
26 treatment alters SARS-CoV-2 infectivity and severity of COVID-19. Our data suggest

1 that the hypertension-associated additional risk for critical disease progression can be
2 reduced by ARB treatment and is almost abolished by ACEi treatment. This is
3 corroborated by previous reports observing higher mortality rates in hypertensive
4 COVID-19 patients in the absence of ACEi/ARB treatment³².

5 Several clinical studies are now available comparing SARS-CoV-2 infectivity rates
6 among patients with and without ACEi/ARB treatment^{13, 33}. Their findings support the
7 notion that testing positive for SARS-CoV-2 is not associated with treatment by
8 ACEi/ARB^{13, 34}. In line, we observe no difference in *ACE2* expression and initial viral
9 concentration between patient groups. Also, induction of *ACE2* expression after SARS-
10 CoV-2-infection was not altered by ACEi/ARB treatment. However, viral clearance was
11 delayed by ARB treatment. While reduced viral clearance can be a result of defects in
12 immunity for example of an impaired T cell activity, as it has already been reported for
13 cardiovascular diseases³⁵, our data suggest that the altered anti-viral-response of
14 ciliated and secretory epithelial cells plays a crucial role. Intrinsic anti-viral response
15 was dampened in ARB-treated patients, while patients under ACEi treatment showed
16 similar viral clearance as normotensive patients together with an elevated intrinsic
17 antiviral response.

18 We identified hypertension-associated elevated immunological activity as the
19 prominent factor contributing to the increased risk of hypertensive patients for COVID-
20 19 severity. Hypertensive patients showed an inflammatory predisposition of different
21 immune cell subtypes observed already before SARS-CoV-2 infection irrespective of
22 anti-hypertensive treatment. Upon SARS-CoV-2 infection, ARB-treated patients
23 showed an exaggerated hyperinflammatory response, which was alleviated in ACEi
24 treated patients. This distinct inflammatory response of COVID-19 patients under
25 different anti-hypertensive treatment may also give rise to the here described less
26 pronounced risk reduction for disease severity under ARB compared to ACEi therapy.

1 Interestingly, a recent study showed enhanced plasma ACE2-activity along with a
2 significant increase in Ang(1-7) concentrations in ACEi treated COVID-19 patients
3 compared to COVID-19 patients under ARB therapy, suggesting a higher anti-
4 inflammatory capacity in ACEi compared to ARB treated COVID-19³⁶.

5 The present study demonstrated an immune activation in hypertensive patients that is
6 largely augmented under COVID-19 and may provide a novel explanation for the
7 adverse course of the disease in these patients related to a hyperinflammatory
8 response. Our data are in line with the general guideline recommendations
9 discouraging discontinuation of ACEi or ARB treatment. On the contrary, our results
10 may suggest that ACEi could be the more beneficial antihypertensive treatment during
11 COVID-19. A randomized control trial is required to assess the clinical impact of ACEi
12 vs. ARB treatment in COVID-19 patients and several trials are under way.

13

14

15 **References**

- 16 1. Grasselli, G. et al. Risk Factors Associated With Mortality Among Patients
17 With COVID-19 in Intensive Care Units in Lombardy, Italy. *JAMA Intern Med*,
18 E1-E11 (2020).
- 19 2. Gupta, S. et al. Factors Associated With Death in Critically Ill Patients With
20 Coronavirus Disease 2019 in the US. *JAMA Intern Med*, E1-E12 (2020).
- 21 3. Danaei, G. et al. National, regional, and global trends in systolic blood
22 pressure since 1980: systematic analysis of health examination surveys and
23 epidemiological studies with 786 country-years and 5.4 million participants.
24 *Lancet* **377**, 568-577 (2011).

- 1 4. Huang, S. et al. COVID-19 patients with hypertension have more severe
2 disease: a multicenter retrospective observational study. *Hypertens Res* **43**,
3 824-831 (2020).
- 4 5. Mancia, G., Rea, F., Ludergnani, M., Apolone, G. & Corrao, G. Renin-
5 Angiotensin-Aldosterone System Blockers and the Risk of Covid-19. *N Engl J*
6 *Med* **382**, 2431-2440 (2020).
- 7 6. Gao, C. et al. Association of hypertension and antihypertensive treatment with
8 COVID-19 mortality: a retrospective observational study. *Eur Heart J* **41**,
9 2058-2066 (2020).
- 10 7. Hoffmann, M. et al. SARS-CoV-2 Cell Entry Depends on ACE2 and TMPRSS2
11 and Is Blocked by a Clinically Proven Protease Inhibitor. *Cell* **181**, 271-280
12 (2020).
- 13 8. Paz Ocaranza, M. et al. Counter-regulatory renin-angiotensin system in
14 cardiovascular disease. *Nat Rev Cardiol* **17**, 116-129 (2020).
- 15 9. Romero, C.A., Orias, M. & Weir, M.R. Novel RAAS agonists and antagonists:
16 clinical applications and controversies. *Nat Rev Endocrinol* **11**, 242-252
17 (2015).
- 18 10. Soler, M.J., Barrios, C., Oliva, R. & Batlle, D. Pharmacologic modulation of
19 ACE2 expression. *Curr Hypertens Rep* **10**, 410-414 (2008).
- 20 11. Vaduganathan, M. et al. Renin-Angiotensin-Aldosterone System Inhibitors in
21 Patients with Covid-19. *N Engl J Med* **382**, 1653-1659 (2020).
- 22 12. Jarcho, J.A., Ingelfinger, J.R., Hamel, M.B., D'Agostino, R.B., Sr. & Harrington,
23 D.P. Inhibitors of the Renin-Angiotensin-Aldosterone System and Covid-19. *N*
24 *Engl J Med* **382**, 2462-2464 (2020).
- 25 13. Reynolds, H.R. et al. Renin-Angiotensin-Aldosterone System Inhibitors and
26 Risk of Covid-19. *N Engl J Med* **382**, 2441-2448 (2020).

- 1 14. Dinh, Q.N., Drummond, G.R., Sobey, C.G. & Chrissobolis, S. Roles of
2 inflammation, oxidative stress, and vascular dysfunction in hypertension.
3 *Biomed Res Int* **2014**, 406960 (2014).
- 4 15. Jayedi, A. et al. Inflammation markers and risk of developing hypertension: a
5 meta-analysis of cohort studies. *Heart* **105**, 686-692 (2019).
- 6 16. Chua, R.L. et al. COVID-19 severity correlates with airway epithelium-immune
7 cell interactions identified by single-cell analysis. *Nat Biotechnol*, 970-979
8 (2020).
- 9 17. Liao, M. et al. Single-cell landscape of bronchoalveolar immune cells in
10 patients with COVID-19. *Nat Med* **26**, 842-844 (2020).
- 11 18. Richardson, S. et al. Presenting Characteristics, Comorbidities, and Outcomes
12 Among 5700 Patients Hospitalized With COVID-19 in the New York City Area.
13 *JAMA*, 2052-2059 (2020).
- 14 19. Liu, S. et al. Clinical characteristics and risk factors of patients with severe
15 COVID-19 in Jiangsu province, China: a retrospective multicentre cohort
16 study. *BMC Infect Dis* **20**, 1-9 (2020).
- 17 20. Benelli, G. et al. SARS-COV-2 comorbidity network and outcome in
18 hospitalized patients in Crema, Italy. *preprint at*
19 <https://doi.org/10.1101/2020.04.14.20053090> (2020).
- 20 21. Kurth, F. et al. Studying the pathophysiology of coronavirus disease 2019: a
21 protocol for the Berlin prospective COVID-19 patient cohort (Pa-COVID-19).
22 *Infection* **48**, 619-626 (2020).
- 23 22. Lukassen, S. et al. SARS-CoV-2 receptor ACE2 and TMPRSS2 are primarily
24 expressed in bronchial transient secretory cells. *EMBO J* **39**, e105114 (2020).
- 25 23. Hou, Y.J. et al. SARS-CoV-2 Reverse Genetics Reveals a Variable Infection
26 Gradient in the Respiratory Tract. *Cell*, 429-446 (2020).

- 1 24. Nawijn, M.C. & Timens, W. Can ACE2 expression explain SARS-CoV-2
2 infection of the respiratory epithelia in COVID-19? *Mol Syst Biol* **16**, e9841
3 (2020).
- 4 25. Park, A. & Iwasaki, A. Type I and Type III Interferons - Induction, Signaling,
5 Evasion, and Application to Combat COVID-19. *Cell Host Microbe* **27**, 870-
6 878 (2020).
- 7 26. Taniguchi, K. & Karin, M. NF-kappaB, inflammation, immunity and cancer:
8 coming of age. *Nat Rev Immunol* **18**, 309-324 (2018).
- 9 27. Liu, T., Zhang, L., Joo, D. & Sun, S.C. NF-kappaB signaling in inflammation.
10 *Signal Transduct Target Ther* **2**, e17023 17021-17029 (2017).
- 11 28. Neufeldt, C.J. et al. SARS-CoV-2 infection induces a pro-inflammatory
12 cytokine response through cGAS-STING and NF-κB. *preprint at*
13 <https://doi.org/10.1101/2020.07.21.212639> (2020).
- 14 29. Efremova, M., Vento-Tormo, M., Teichmann, S.A. & Vento-Tormo, R.
15 CellPhoneDB: inferring cell-cell communication from combined expression of
16 multi-subunit ligand-receptor complexes. *Nat Protoc* **15**, 1484-1506 (2020).
- 17 30. Guan, W.J. et al. Comorbidity and its impact on 1590 patients with COVID-19
18 in China: a nationwide analysis. *Eur Respir J* **55**, 1-14 (2020).
- 19 31. Sanyaolu, A. et al. Comorbidity and its Impact on Patients with COVID-19. *SN*
20 *Compr Clin Med*, 1-8 (2020).
- 21 32. Zhang, P. et al. Association of Inpatient Use of Angiotensin-Converting
22 Enzyme Inhibitors and Angiotensin II Receptor Blockers With Mortality Among
23 Patients With Hypertension Hospitalized With COVID-19. *Circ Res* **126**, 1671-
24 1681 (2020).
- 25 33. Chung, M.K. et al. SARS-CoV-2 and ACE2: The biology and clinical data
26 settling the ARB and ACEI controversy. *EBioMedicine* **58**, 102907 (2020).

- 1 34. Mehta, N. et al. Association of Use of Angiotensin-Converting Enzyme
2 Inhibitors and Angiotensin II Receptor Blockers With Testing Positive for
3 Coronavirus Disease 2019 (COVID-19). *JAMA Cardiol*, 1-8 (2020).
- 4 35. Nyambuya, T.M., Dlodla, P.V., Mxinwa, V. & Nkambule, B.B. T-cell activation
5 and cardiovascular risk in adults with type 2 diabetes mellitus: A systematic
6 review and meta-analysis. *Clin Immunol* **210**, 108313 108311-108312 (2020).
- 7 36. Kintscher, U. et al. Plasma Angiotensin Peptide Profiling and ACE2-Activity in
8 COVID-19 Patients treated with Pharmacological Blockers of the Renin
9 Angiotensin System. *Hypertension*, 1-4 (2020).
- 10
11

1 **Methods**

2

3 ***Patient Recruitment and Ethics Approval***

4 Patients were enrolled between March 6th and June 7th 2020 in either the prospective
5 observational cohort study Pa-COVID-19²¹ at Charité – Universitätsmedizin Berlin or
6 the SC2-study at the University Hospital Leipzig. Written informed consent was given
7 by all patients or their legal representatives. The study was approved by the respective
8 Institutional Review boards of the Charité-Universitätsmedizin Berlin (EA2/066/20) or
9 the University Hospital Leipzig (123/20-ek) and conducted in accordance with the
10 Declaration of Helsinki.

11

12 ***Pa-COVID-19 cohort***

13 Between March–May 2020, 162 COVID-19-positive patients were recruited at Charité
14 – Universitätsmedizin Berlin in the Pa-COVID-19 study. In the here presented study,
15 we excluded those patients who had their positive SARS-CoV-2 test exclusively
16 outside the Charité (n=12) and those with missing information on ACEi/ARB treatment
17 (n=6). For the remaining 144 COVID-19 patients, we assessed differences in COVID-
18 19 severity related to pre-existing cardiovascular diseases (CVD+), such as
19 hypertension (HT+/CVD-) or HT and an additional cardiovascular disease (coronary
20 artery disease and/or heart failure, HT+/CVD+) in the different treatment groups
21 (ACEi+, ARB+, ACEi-/ARB-) compared to patients without HT-/CVD-. HT was defined
22 according to ESC/ESH guidelines as office blood pressure ≥ 140 mm Hg systolic or \geq
23 90 mm Hg diastolic³⁷. The characteristics of this cohort are summarized in
24 Supplementary Table 1 and 2.

25

26 ***Single-cell RNA sequencing cohort***

1 We collected nasopharyngeal swabs for single-cell RNA transcriptome analyses
2 (scRNA-seq) of 32 confirmed COVID-19 patients (23 males and nine females; median
3 age: 67; range: 32–91 years of age) and 16 controls without any COVID-19 related
4 symptoms (nine males, seven females; median age: 53; range: 24-79). Relevant
5 patient characteristics are given in Supplementary Table 3.

6 Of the COVID-19 patients, 23 patients were classified as having severe, and nine as
7 having critical disease according to the World Health Organization (WHO) guidelines³⁸.
8 Hospital mortality of these patients was 1/33 (3.0%).

9 Baseline CVD were prevalent in 25 of the COVID-19 patients. They either suffered
10 from HT only (n=16, 64%), CVD with HT (n=7, 28%), or CVD with heart failure and HT
11 (n=2, 8%). Patients with HT only were classified as HT+, while all patients suffering
12 from HT and CVD (and possibly additionally heart failure) were classified as
13 HT+/CVD+. Concomitant treatment of HT+/CVD± included treatment with either ACEi
14 (n=10) or ARB (n=15). Seven of the COVID-19 patients had no known CVD (21.2%).

15 Note that patient BIH-SCV2-14 was included in all analysis regarding ACEi/ARB
16 treatment but not in the CVD analysis (this patient suffered from HT and heart failure).

17 Of the symptom-free SARS-CoV-2-negative patients, six had HT only (37.5%), and
18 four had additional CVD (25%). Six of these patients received ACEi (37.5%) and four
19 were treated with ARB (25%). The remaining six patients had no known CVD and
20 therefore, were neither treated with ACEi nor ARB (37.5%).

21

22 ***Isolation and preparation of single cells from human airway specimens, followed***
23 ***by pre-processing of the raw sequencing reads***

24 Sample procurement, single-cell isolation, library preparation, and subsequent data
25 analysis was performed as described previously¹⁶. Briefly, freshly taken
26 nasopharyngeal swabs from donors were directly transferred into 500 µL cold

1 DMEM/F12 medium (Gibco, 11039) and 500 μ L of 13mM DTT (AppliChem, A2948)
2 were added to each sample. Cells were released by gently pipetting the solution onto
3 the swab, followed by dipping the swab 20 times into the medium. Subsequently, the
4 samples were incubated on a thermomixer at 37°C, 500 rpm for 10 minutes, followed
5 by centrifugation at 350xG at 4°C for 5 minutes. While carefully removing the
6 supernatant, the pellet was visually examined for any traces of blood. If it contained
7 red blood cells (RBC), the pellet was resuspended in 500 μ L 1x PBS (Sigma-Aldrich,
8 D8537) and 1 mL of RBC Lysis Buffer (Roche, 11814389001), incubated at 25°C for
9 10 minutes, and subsequently centrifuged at 350xG at 4°C for 5 minutes. A single cell
10 suspension was achieved by resuspending the cell pellet in 500 μ L Accutase (Thermo
11 Fisher, 00-4555-56), followed by incubation at room temperature for 10 minutes with
12 gently mixing the cells after 5 minutes by pipetting. Subsequently, 500 μ L DMEM/F12
13 supplemented with 10% FBS was added to the cells. After centrifugation at 350xG at
14 4°C for 5 minutes and removal of the supernatant, the cell pellet was resuspended in
15 100-500 μ L 1x PBS (depending on the size of the cell pellet). Cell debris was removed
16 by using a 35 μ m cell strainer (Falcon, 352235) before cell counting was performed
17 using a disposable Neubauer chamber (NanoEnTek, DHC-N01). The cell suspension
18 was loaded into the 10x Chromium Controller using the 10x Genomics Single Cell 3'
19 Library Kit v3.0 (10x Genomics; PN 1000076; PN 1000077; PN 1000078) and 10x
20 Genomics Single Cell 3' Library Kit v3.1 (10x Genomics; PN 1000223; PN 1000157;
21 PN 1000213; PN 1000122) and the subsequent reverse transcription, cDNA
22 amplification, and library preparation was performed according to the manufacturer's
23 instructions. Importantly, we extended the incubation at 85°C during the reverse
24 transcription to 10 minutes to ensure virus inactivation. Afterwards, the 3'RNA
25 sequencing libraries were pooled either for S2 or S4 flow cells (S2: up to eight samples,

1 S4: up to 20 samples) and sequenced on the NovaSeq 6000 Sequencing System
2 (Illumina, paired-end, single-indexing).
3 All samples were processed under biosafety S3 within one hour after procurement.
4 Note that samples not immediately used for library preparation were resuspended in
5 cryopreservation medium [20% FBS (Gibco, 10500), 10% DMSO (Sigma-Aldrich,
6 D8418), 70% DMEM/F12] and stored at -80°C. Frozen cells were thawed quickly at
7 37°C, pelleted at 350xG at 4°C for 5 minutes, and proceeded with normal processing.

8 Single-cell datasets were processed using cellranger 3.0.1. All transcripts were aligned
9 to a customized human hg19 reference genome (10x genomics, version 3.1.0) plus
10 the SARS-CoV-2 genome (Refseq-ID: NC_045512) added as an additional
11 chromosome. Following alignment, ambient RNA was removed using SoupX³⁹ using
12 *MUC1*, *MUC5AC*, and *MUC5B* as marker genes. Where ambient RNA levels seemed
13 plausible (5-15%), filtered expression matrices were used for downstream analyses.

14 Further processing was performed using Seurat 3.1.4. Genes were retained if they
15 were present in at least three cells in a sample. Cells with more than or equal to 15%
16 mitochondrial reads or less than 200 genes expressed were removed from the
17 analysis. For the number of UMIs, an upper cutoff was chosen manually per sample
18 based on outliers in a UMI counts vs. gene counts plot and was typically in the range
19 of 75,000 to 150,000. After normalizing to 10,000 reads per cell, samples were
20 integrated using stepwise CCA on smaller subsets using 90 components and 2,000
21 variable genes identified by SelectIntegrationFeatures. On the integrated dataset, PCA
22 was run using 90 principal components, followed by UMAP and clustering with a
23 resolution of 2.1, both using all components. NKT, CTL, and p-NKT cells were
24 subsetted for further analysis. Scaling, dimensional reduction by PCA and the UMAP
25 was calculated separately for this subset.

1 Cell types were then refined manually by assessing the expression of known cell type
2 markers. Cell types from epithelial^{22, 40, 41} and immune⁴² cell populations were identified
3 according to the expression levels of different marker genes (Extended Data Figure
4 1c). The “viral responsive” cell states of ciliated and squamous epithelial cells
5 (Extended Data Figure 1b) were identified by gene set enrichment analysis using
6 clusterProfiler version 3.12.0 and the output of “FindClusters()” function from Seurat
7 as input (<https://yulab-smu.github.io/clusterProfiler-book/index.html>)⁴³.

8 For cell-cell interactions, which are based on the expression of known ligand-receptor
9 pairs in different identified cell types, CellPhoneDB²¹ version 2.1.2 was used
10 (<https://github.com/Teichlab/cellphonedb>). circlize 0.4.10 was used to generate the
11 circos plots to display the cell-cell interactions⁴⁴.

12 Shifts of interactions across the different conditions were tested for significance using
13 a logistic regression based on a binomial distribution (Supplementary Table 5).
14 Arboreto⁴⁵ 0.1.5 and pySCENIC⁴⁶ 0.10.0 were used to infer transcription factor
15 importance.

16

17 ***Viral load measurement***

18 SARS-CoV-2 RT-PCR results and SARS-CoV-2 RNA concentrations were obtained
19 by using respiratory samples taken for routine testing and by using two different test
20 systems. First, by using an assay targeting the SARS-CoV-2 E-gene as published
21 before⁴⁷ and the Roche LC480 instrument. Second, by using the cobas® SARS-CoV-
22 2 test on the cobas® 6800/ 8800 system. In cases of the LC480 system, RNA was
23 extracted by using the MagNA Pure 96 DNA and Viral NA Small Volume Kit on a Roche
24 MagNA Pure 96 system. We quantified SARS-CoV-2 RNA by applying external
25 calibration curves and quantified *in vitro* transcribed RNA, derived from the E-gene
26 fragment⁴⁷ or purified complete SARS-CoV-2 RNA. Viral load (using the E-gene

1 genome target for both test systems) was calculated taking into account different
2 predilutions, extraction volumes, and RT-PCR reaction volumes.

3

4 ***Viral load assessment by regression analysis***

5 Data on positive viral mRNA measurements were available for 144 patients of the Pa-
6 COVID-19 cohort. To smooth the longitudinal viral mRNA data of each patient, the
7 values were binned in three-day intervals with respect to the time of the first test result.
8 The maximal value in each bin was considered. In case a patient had a negative test
9 for SARS-CoV-2 between two positive measurements, the negative result was
10 disregarded. Patients for which only one negative test result was available or had
11 missing confounder information were excluded from the analysis. A linear repeated
12 measurement mixed model assuming a heterogeneous first-order autoregressive
13 structure of the covariance matrix was applied considering ACEi or ARB treatment in
14 comparison to untreated patients without pre-existing CVD - otherwise treated
15 HT+/CVD+/- patients were excluded - as a fixed effect. The concentration
16 measurements up to the fifth consecutive viral test were included in the model that
17 was adjusted for days post onset of symptoms, gender, BMI, smoking, and insulin
18 treatment. Calculations were performed in SPSS version 25 and predicted means
19 calculated using the maximum likelihood option.

20

21 ***Slope analysis of viral clearance***

22 To compare the rate of viral clearance between patient groups, we performed a linear
23 fit to viral load measurements during the first 30 days post symptom onset. Zero
24 measurements, and patients with fewer than four non-zero measurements within this

1 timeframe, were excluded from this analysis. Student's t-tests were used to identify
2 statistically significant differences in slope between groups.

3

4 ***Identification of RIG-I and type I/III interferon responsive gene sets***

5 A549 cells were electrotransfected with 400bp long in vitro transcribed dsRNA⁴⁸ and
6 lysed at 2, 4, 6, 8, 16 and 24h after transfection, or mock electrotransfected and lysed
7 at 2 and 24h. Alternatively, A549 cells were treated with a mix of 100 IU/ml interferon
8 beta (8499-IF-010/CF, R&D Systems, Minneapolis, MN, USA) and 2.5 ng/ml interferon
9 lambda-1 (300-02L-100, Peprotech, Hamburg, Germany) for 2, 8 or 24h and then lysed.
10 Total RNA was extracted from cell lysates using the NucleoSpin RNA Plus kit
11 (Macherey Nagel, Düren, Germany) and the RNA was subjected to microarray
12 analyses using the Illumina Human HT-12 Expression Beadchip platform at the
13 genomic and proteomics core facility at DKFZ. Expression data was quantile
14 normalized, genes with no significant expression at any condition / time point were
15 excluded and gene regulation at different treatment time points vs. the 0h control was
16 determined using the limma package (Bioconductor). Data were then filtered according
17 to the following criteria to define gene sets.

18 The gene set "Cell-intrinsic antiviral (RIG-I-like receptor, RLR) signaling" comprises
19 genes that were exclusively or predominantly upregulated upon dsRNA transfection
20 (RLR stimulation) but not upon IFN treatment; while for the sake of specificity a very
21 specific RIG-I stimulation was applied, the transcriptional response likely is similar for
22 any antiviral stimulus (e.g. through MDA5, STING, TLRs) that activates the IRF3
23 transcription factor. The Cut-offs were as follows: maximum (at any time point) log₂-
24 fold change in dsRNA transfected samples (maxLog₂FC-RNA) > 2.0 and maximum
25 log₂-fold change in IFN treated samples (maxLog₂FC-IFN) <1.0; genes were excluded
26 as electrotransfection artifacts if maximum log₂-fold change in mock transfection

1 (maxLog2FC-mock) > 0.5*(maxLog2FC-RNA – maxLog2FC-IFN) (11 genes). This
2 procedure yielded a list of 238 genes, comprising expected genes such as the IRF3-
3 dependent type I and III IFN genes themselves (*IFNB1*, *IFNL1,2,3*) and classical NFkB
4 targets such as *TNFAIP3* (previously *A20*) and the IκB genes *NFKBIA*, *NFKBIB*,
5 *NFKBIZ*.

6 The gene set “Extrinsic / paracrine type I / III IFN signaling” comprises genes that were
7 strongly upregulated by extrinsic IFN beta / IFN lambda treatment while less so by cell-
8 intrinsic RLR induction. Note that the majority of IFN-induced genes were upregulated
9 by RLR signaling as well, putatively due to the above noted IFN production upon RLR
10 stimulation. We enriched this gene set for genes with a bias towards IFN and against
11 RLR signaling by applying the below described filters. Notably, a few genes, such as
12 *LY6E*, described to possess antiviral activity against SARS-CoV-2⁴⁹, were induced
13 only upon IFN treatment but not at all by RLR signaling. In general, we found less
14 profound gene induction in IFN-treated than in dsRNA transfected conditions, likely
15 due to the moderate dose of IFN used; we therefore used less stringent cut-offs for this
16 gene set: maxLog2FC-IFN > 0.8 and (maxLog2FC-IFN - maxLog2FC-RNA) > -0.5.
17 The latter filter removed roughly 50% of the genes, selecting for those with a relative
18 bias of IFN-treatment over dsRNA transfection. Filtering yielded 95 genes, including
19 many of the well-known *ISGF3*-driven IFN-stimulated genes (ISGs), including the MX-
20 family genes, *IFIT1*, *IFITM2/3* and *ISG15*.

21

22 **Statistics**

23 Differences in the percentage of *ACE2* expressing cells were calculated using logistic
24 regression in R 3.5.1. 95% confidence intervals for the percentage of *ACE2* expressing
25 cells are provided. Differences in gene expression were calculated using
26 “FindMarkers()” in Seurat version 3.1.4 with the MAST-based differential expression

1 test adjusted for days post symptoms onset (dps). Overlap statistics were calculated
2 as hypergeometric tail probabilities. Differences in CPM were calculated using an
3 ANOVA followed by Tukey's honest significance of differences test after assessing
4 homoskedasticity using Bartlett's test. When multiple tests were performed, p-values
5 were adjusted using the Benjamini-Hochberg method. Total CPM values were
6 extracted from the filtered and raw matrices output by CellRanger. Motif enrichment p-
7 values were calculated using HOMER 4.10.0⁵⁰. To analyze the potential contribution
8 of HT/CVD and its treatment on COVID-19 severity in the PaCOVID-19 cohort we
9 conducted chi-square tests with Yates' correction and logistic regression models
10 adjusted for gender, BMI smoking and insulin treatment. Age showed collinearity with
11 ACEi or ARB treatment. Therefore, age was omitted as a confounder in models where
12 ACEi or ARB treatment was used as an independent variable. Viral clearance was
13 assessed based on similarly adjusted linear regression models as described above.
14 Logistic regression models assessing gene expression changes observed in the
15 scRNA-seq cohort were adjusted for age, gender, days post onset of symptoms and
16 study center.

17

18 ***Data availability***

19 Due to potential risk of de-identification of pseudonymized RNA sequencing data the
20 raw data will be available under controlled access in the EGA repository, [will be added
21 upon manuscript acceptance]. Count and metadata tables (patient-ID, sex, age, cell
22 type, QC metrics per cell) can be found at FigShare: [will be added upon manuscript
23 acceptance]. In addition, these data can be further visualized and analyzed in the
24 Magellan COVID-19 data explorer at <https://digital.bihealth.org> [will be publicly
25 available upon manuscript acceptance].

26

1 **Code availability**

2 No custom code was generated/ used during the current study.

3

4 **Online Methods References**

- 5 37. Williams, B. et al. 2018 ESC/ESH Guidelines for the management of arterial
6 hypertension: The Task Force for the management of arterial hypertension of
7 the European Society of Cardiology and the European Society of
8 Hypertension: The Task Force for the management of arterial hypertension of
9 the European Society of Cardiology and the European Society of
10 Hypertension. *J Hypertens* **36**, 1953-2041 (2018).
- 11 38. Aylward, B., Liang, W. & WHO-China-Joint-Mission Report of the WHO-China
12 Joint Mission on Coronavirus Disease 2019 (COVID-19). *published on the*
13 *WHO website, document can be found at [\(https://www.who.int/publications-](https://www.who.int/publications-detail/report-of-the-who-china-joint-mission-on-coronavirus-disease-2019-(covid-19))*
14 *detail/report-of-the-who-china-joint-mission-on-coronavirus-disease-2019-*
15 *(covid-19) (page 12) (2020).*
- 16 39. Young, M. & Behjati, S. SoupX removes ambient RNA contamination from
17 droplet based single-cell RNA sequencing data. *preprint at*
18 *<https://doi.org/10.1101/303727> (2020).*
- 19 40. Plasschaert, L.W. et al. A single-cell atlas of the airway epithelium reveals the
20 CFTR-rich pulmonary ionocyte. *Nature* **560**, 377-381 (2018).
- 21 41. Vieira Braga, F.A. et al. A cellular census of human lungs identifies novel cell
22 states in health and in asthma. *Nat Med* **25**, 1153-1163 (2019).
- 23 42. Travaglini, K.J. et al. A molecular cell atlas of the human lung from single cell
24 RNA sequencing. *preprint at <https://doi.org/10.1101/742320> (2019).*

- 1 43. Yu, G., Wang, L.G., Han, Y. & He, Q.Y. clusterProfiler: an R package for
2 comparing biological themes among gene clusters. *OMICS* **16**, 284-287
3 (2012).
- 4 44. Gu, Z., Gu, L., Eils, R., Schlesner, M. & Brors, B. circlize Implements and
5 enhances circular visualization in R. *Bioinformatics* **30**, 2811-2812 (2014).
- 6 45. Moerman, T. et al. GRNBoost2 and Arboreto: efficient and scalable inference
7 of gene regulatory networks. *Bioinformatics* **35**, 2159-2161 (2019).
- 8 46. Aibar, S. et al. SCENIC: single-cell regulatory network inference and
9 clustering. *Nat Methods* **14**, 1083-1086 (2017).
- 10 47. Corman, V.M. et al. Detection of 2019 novel coronavirus (2019-nCoV) by real-
11 time RT-PCR. *Euro Surveill* **25**, 1-8 (2020).
- 12 48. Binder, M. et al. Molecular mechanism of signal perception and integration by
13 the innate immune sensor retinoic acid-inducible gene-I (RIG-I). *J Biol Chem*
14 **286**, 27278-27287 (2011).
- 15 49. Pfaender, S. et al. LY6E impairs coronavirus fusion and confers immune
16 control of viral disease. *Nat Microbiol* (2020).
- 17 50. Heinz, S. et al. Simple combinations of lineage-determining transcription
18 factors prime cis-regulatory elements required for macrophage and B cell
19 identities. *Mol Cell* **38**, 576-589 (2010).
- 20
21

22 **Acknowledgement**

23 We thank all patients of the Pa-COVID-19 cohort study for kindly donating
24 nasopharyngeal samples and clinical data. We also thank Alexander Krannich and
25 Julia Kazmierski, Charité – Universitätsmedizin Berlin, for help in sample
26 procurement/annotation and for supporting sample processing, respectively. We thank

1 Antje Seidel and Grit Szczepankiewicz for supporting patient recruitment at the
2 University Hospital Leipzig. We thank Carola Spann and Darius Schweinoch for their
3 help with the *in vitro* experiment. This study was supported by the BIH COVID-19
4 research program, the European commission (ESPACE, 874719, Horizon 2020), the
5 BMBF-funded de.NBI Cloud within the German Network for Bioinformatics
6 Infrastructure (de.NBI; 031A537B, 031A533A, 031A538A, 031A533B, 031A535A,
7 031A537C, 031A534A, 031A532B), and the BMBF-funded Medical Informatics
8 Initiative (HiGHmed, 01ZZ1802A - 01ZZ1802Z). We thank Illumina GmbH for financial
9 support via the allocation of reagents and sequencing flow cells as well as Markus
10 Vossmann, Martin Allgaier, Oliver Krätke for the realization of the sequencing runs at
11 the Illumina Solutions Center Berlin. MSA has received research support from the
12 German Cardiovascular Research Center.

13

14 **Authors contributions**

15 R.E., C.C., U.L., I.L. conceived, designed, and supervised the project. V.C. and C.D.
16 performed qPCR experiments and/or provided the data, Sa.T., S.L., R.L.C. L.T., T.K.,
17 C.K. performed data analysis. Jo.L., R.L.C., Je.L., M.M. performed the single-cell RNA
18 sequencing experiments. M.B. performed and analyzed the *in vitro* experiment. Je.L.,
19 C.K., M.M., J.K., F.P. provided experimental support. M.S.A, S.H., A.L., B.H., F.K.,
20 M.W., M.T.V., S.D.M, U.G.L., L.-E.S. and Sv.L. provided the human specimens, clinical
21 data and annotation of the patients. Sa.T. and B.P.H. managed patient data of the
22 cohort. Sv.T., J-P.A., J.E. provided technical and data management support. Sv.T.
23 developed Magellan. B.P.H., C.G., N.I., L.K. and U.L. contributed with discussion of
24 the results. Sa.T., Sv.L., S.L., R.L.C., L.T., B.P.H., R.E. and I.L. wrote and prepared
25 the manuscript. All authors read, revised, and approved the manuscript.

26

1 **Competing Interest Statement**

2 MSA has received personal fees from Servier outside the submitted work. All other
3 authors not declare any competing interest.

4

5 **Main Figures**

6 **Figure 1. Association of anti-hypertensive treatment with COVID-19 severity and** 7 **viral clearance.**

8 (a) Comparison of COVID-19 severity based on WHO-classification in patients without
9 cardiovascular comorbidities (HT-/CVD-, n=54) and those with arterial hypertension
10 and cardiovascular disease (HT+/CVD±, n=90). CVD patients were separated in those
11 with HT only (HT+/CVD-, n=63) and those with additional cardiovascular diseases
12 (HT+/CVD+, n=27) and are depicted dependent on their treatment with ARB (ARB+),
13 ACEi (ACEi+) or other medications (ACEi-/ARB-). *p-value <0.05 based on a Yates-
14 corrected chi-square comparison of critical vs. all other WHO categories. (b) Viral
15 clearance over time shown for SARS-CoV-2 positive patients without a pre-existing
16 cardiovascular disease (CVD-/HT-, n=46) in comparison to ARB+ (n=25) or ACEi+
17 (n=21) HT+/CVD± COVID-19 patients. Depicted are mean +/- SD of qPCR data binned
18 in 3-day intervals, only the maximal value of each patient in this interval was
19 considered. Adjusted regression analysis (confounder: BMI, gender, smoking, insulin-
20 treatment, days post onset of symptoms, n=92) showed a significantly higher viral load
21 for ARB+/ HT+/CVD±, compared to ACEi+/ HT+/CVD± and HT-/CVD- patients.

22

23 **Figure 2. Characteristics of the scRNA-seq cohorts and cell type distribution of** 24 **nasopharyngeal samples.**

25 (a) COVID-19 patients were analysed by scRNA-seq to study the impact of HT/CVD
26 and its treatment by ARB or ACEi in SARS-CoV-2 negative (n=16) and positive

1 patients (n=32). (b) Samples were collected from the nasopharynx of the patients and
2 subjected to scRNA-seq resulting in the given UMAP displaying all identified cell types
3 and states (color-coded). (c) Distribution of selected immune cell types/states in SARS-
4 CoV-2 negative and positive patients separated by HT+/CVD± / HT-/CVD- or
5 ACEi+/ARB+ treatment. Given are percentages related to the total number of immune
6 cells. MC = mast cells; moMa = monocyte derived macrophage; Neu = neutrophil;
7 (n)rMa = (non-)resident macrophage; p-NKT = proliferating natural killer T-cell; CTL =
8 cytotoxic T lymphocyte. *significance compared to CVD-/HT-, # significance compared
9 to SARS-CoV-2 neg.

10

11 **Figure 3: Differential regulation of antiviral response in patients with different**
12 **anti-hypertensive treatments**

13 (a) Scaled heatmaps showing the top 100 genes differentially expressed between
14 SARS-CoV-2-positive ACEi+ or ARB+ and HT-/CVD- patients in ciliated and secretory
15 cells by RNA sequencing (scaling by column). Enriched pathways (cf. Extended Data
16 Figure 5a) and genes shown in b) are selectively marked next to heatmaps. (b,c)
17 Expression plots of genes involved in regulation of viral genome replication in ciliated
18 and secretory cells, respectively. Red circles indicate Benjamini-Hochberg adjusted
19 two-tailed negative binominal p -value <0.05 . Plotting labels on the right side. (d)
20 Schematic layout of comparative overlap analysis of *in vitro* experiments (A549 lung
21 cell culture) and single cell RNA sequencing of nasal swaps, displaying the workflow
22 for generation of gene sets used in (e) and (f). For further details see Methods. (e) Bar
23 plots showing the linear fold change of enrichment of overlap between the gene sets
24 generated as shown in d) (intrinsic and extrinsic, left and right panel, respectively). The
25 differentially regulated gene sets were split into up- and downregulated genes, which
26 are displayed separately as positive and negative values on the x-axis, respectively.

1 Asterisks indicate adjusted p-values derived from a hypergeometric test for overlap. *:
2 $p < 0.05$, **: $p < 0.01$, ***: $p < 0.001$. (f) Iconized table indicating the direction and
3 strength of enrichment shown in e). Upward pointing arrows mark an enriched overlap
4 in upregulated genes (ARB+ vs. HT-/CVD- and ACEi+ vs. HT-/CVD-), downward
5 pointing arrows an enriched overlap in downregulated genes. Circles indicate that no
6 significant enrichment of overlap is observed. The numbers of patients cohorts are,
7 SARS-CoV-2- HT-/CVD-: n=6, SARS-CoV-2- ACEi+: n=6, SARS-CoV-2- ARB+: n=4,
8 SARS-CoV-2+ HT-/CVD-: n=7; SARS-CoV-2+ ACEi+: n=10, SARS-CoV-2+ ARB+:
9 n=15.

10

11 **Figure 4: Cell-cell interactions in COVID-19 under anti-hypertensive treatment.**

12 (a) Heatmap depicting the total number of interactions per cell type across the different
13 COVID-19 conditions. Scaled by number of identified interactions. (b) Circos plots of
14 the most highly interactive cells (basal, secretory, ciliated, CTL, neu, nrMa, and rMa,
15 printed in bold) scaled by the number of identified interactions. For circos plots of all
16 cell types refer to Extended Data Figure 6a and 6b. (c) Dot plot showing immune
17 modulatory interactions of nrMa across conditions with the highly interactive cells.
18 Color-coding reflects \log_2 mean expression while the p-value is shown by the dot size.
19 The patient numbers for deriving the different sets were: SARS-CoV-2+ HT-/CVD-: 7;
20 SARS-CoV-2+ ACEi+: 10; SARS-CoV-2+ ARB+: 15; SARS-CoV-2+ HT+/CVD±: 25.

21



22 **Figure 5: Hypertension-related immune response of the upper airway in COVID-** 23 **19.**

24 (a-d) Dot plots depict gene expression of pro-inflammatory mediators, and receptors
25 in macrophages, neutrophils, and T cells of the nasopharynx. Red circles indicate
26 Benjamini-Hochberg adjusted two-tailed negative binominal p -value <0.05 . Samples

1 with no contributing cells per cell type were excluded from analysis. (a) Left panel
2 depicts significant gene expression changes in nrMa of hypertensive patients with
3 (HT+/CVD+, n (SARS-CoV-2-/+) = 4/10) or without an additional CVD (HT+/CVD-, n
4 (SARS-CoV-2-/+) = 6/15) compared to HT-/CVD- patients (n (SARS-CoV-2-/+) =
5 6/6). (a-d) Significantly altered gene expression in rMa, moMa, Neu, NKT, and CTL of
6 hypertensive patients treated either with ARB+ (n (SARS-CoV-2-/+) = 4/15),
7 or ACEi+ (n (SARS-CoV-2-/+) = 6/10) in comparison to HT-/CVD- patients (n (SARS-
8 CoV-2-/+) = 6/6). (e) Average gene expression of *CCL3* and *CCL4* in nrMa and Neu of
9 SARS-CoV-2 negative (n=11 Neu, n=13 nrMa), severe COVID-19 (n=23), and critical
10 COVID-19 patients (n=9). (f) Dot plots show average gene expression level of the
11 MIP-1 encoding genes *CCL3* and *CCL4* across all immune cell types comparing
12 ACEi+ and ARB+. (g) Left panel illustrates the immune cell priming of SARS-CoV-2
13 negative patients towards a pre-inflamed phenotype by HT independent of an ACEi or
14 ARB treatment. Listed are all genes that are upregulated in SARS-CoV-2 negative
15 patients with HT+, HT+/CVD+, ACEi+, and ARB+ in comparison to HT-/CVD-. As
16 depicted in the right panel, upon infection, these genes are less activated during the
17 anti-viral immune response against SARS-CoV-2 in ACEi+ (n=10) compared to ARB+
18 (n=15) treated patients. Shown are all pre-activated genes that are up-regulated in
19 ARB+ (dark blue colored genes) and ACEi+ (light blue colored genes) compared to
20 ACEi and ARB+, respectively. Black genes are not differentially expressed between
21 ARB+ vs. ACEi+ treatment. The hypertension related exacerbated expression
22 of *CCL3*, *CCL4*, and their receptor *CCR1* in Neu, and of *CCL4* in nrMa is associated
23 with an increased risk for a critical clinical course of COVID-19 (genes depicted in dark
24 red).

25 Mann-Whitney U-test: **p*-value<0.05, ***p*-value<0.005, ****p*-value<0.0005, Ave. Exp.
26 = average gene expression, Pct. Exp. = percentage of cells expressing the gene.

Figure 1




	predicted mean		p-value
HT ⁻ /CVD ⁻	5.33	ARB ⁺	0.031
		ACEi ⁺	0.644
ACEi ⁺	5.13	HT ⁻ /CVD ⁻	0.644
		ARB ⁺	0.026
ARB ⁺	6.18	HT ⁻ /CVD ⁻	0.031
		ACEi ⁻	0.026


Figure 2

a

scRNA-seq cohort



c



b







Figure 3






Extended Data Figure 1

a




b




Extended Data Figure 3


a



b





Extended Data Figure 4





Extended Data Figure 5

a


Ciliated cells






Secretory cells



b




Extended Data Figure 6




Extended Data Figure 7


a




b



c



d



Extended Data Figure 1: Slope analyses of viral clearance for Pa-COVID-19 patients.

Slope analyses (a) of the viral clearance related to ACEi or ARB treatment and (b) in relation to hypertension. CVD = cardiovascular disease, HT = hypertension, p-values (p) from Student's t-test.

Extended Data Figure 2: Cell type characteristics of the scRNAseq cohort.

(a) Dotplot depicting marker genes used to identify immune cell types. (b) Dotplot depicting marker genes of epithelial cell types. For dotplots, expression levels are color-coded and the percentage of cells expressing a respective gene is size-coded. (c) GO-term enrichment for differentially expressed genes in the ciliated and squamous ViralResp cell cluster. Number of genes observed per term are depicted, colour indicates adjusted p-values.

Extended Data Figure 3: Cell type distribution in the scRNA-seq cohort.

(a) UMAPs depicting distribution of cell types and states in SARS-CoV-2 negative and positive patients. UMAPs are presented separately for controls (HT-/CVD-), patients with a pre-existing cardiac disease (HT+/CVD \pm) and the treatment thereof (ACEi+ and ARB+, respectively). Pct. Exp. = percentage of cells expressing the gene; Rel. Exp. = relative gene expression. (b) Distribution of immune and epithelial cell types/states in SARS-CoV-2 negative and positive patients separated by HT-/CVD-, HT+/CVD \pm or ARB/ACEi-treatment. Given are percentages related to the total number of immune or epithelial cells respectively. *sign. compared to HT-/CVD-, #sign. compared to SARS-CoV-2 neg.

UMAP = uniform manifold approximation and projection, MC = mast cells; moMa = monocyte derived macrophage; Neu = neutrophil; rMa = (non-)resident macrophage;

p-NKT = proliferating natural killer T-cell; CTL = cytotoxic T lymphocyte; diff = differentiating; ViralResp = viral response.

Extended Data Figure 4: *ACE2* and *TMPRSS2* expression.

Violin plots showing the total *ACE2* and *TMPRSS2* expression per sample in counts per million, split by treatment and infection group. Tukey's p-values for individual comparisons are shown. The patient numbers for the different sets were: SARS-CoV-2- HT-/CVD-: 6; SARS-CoV-2- ACEi+: 6; SARS-CoV-2- ARB+: 4; SARS-CoV-2+ HT-/CVD-: 8; SARS-CoV-2+ ACEi+: 10; SARS-CoV-2+ ARB+: 15.

Extended Data Figure 5: Pathway and transcription factor binding motif enrichment analysis.

(a) Pathway enrichment analysis of gene sets (compare Figure 3a) specific to the condition indicated to the right of each panel in ciliated (two upper panels) and secretory cells (two lower panels) in COVID-19 patients. (b) Heatmap showing the p-values of a motif-enrichment analysis for the gene sets upregulated in secretory cells of ACEi+ or ARB+ vs. HT-/CVD- COVID-19 patients. Linear p-values are indicated as labels, log₁₀ p-values are used for color-coding. The patient numbers for deriving the different sets were: SARS-CoV-2+ HT-/CVD-: 8; SARS-CoV-2+ ACEi+: 10; SARS-CoV-2+ ARB+: 15.

Extended Data Figure 6: Cell-cell interactions in SARS-CoV-2 negative patients.

(a) Heatmap depicting the total number of interactions per cell type across the different SARS-CoV-2- patient conditions. Scaled by the number of identified interactions. (b) Circos plots of highly interactive cells (basal, secretory, ciliated, CTL, Neu, nrMa, and

rMa). Scaled by the number of identified interactions. (c) Heatmap showing interactions per cell type categorized as inter-/intra-compartment interactions for SARS-CoV-2 positive and negative cohorts. Log₂ scaling of the number of identified interactions. (d) Dotplot showing the expression profile of the different immune modulatory factors by the highly interactive cells. Expression levels are color coded; the percentage of cells expressing the respective gene is size coded. Significantly altered expression (Benjamini–Hochberg adjusted two-tailed, negative-binomial $P < 0.05$) in ACEi+ versus HT-/CVD- (circles around ACEi+) and ARB+ versus HT-/CVD- (circles around ARB+) is marked by a red circle. Ave. Exp. = average expression, Pct. Exp. = percentage of cells expressing the gene. The patient numbers for deriving the different sets were: SARS-CoV-2- HT-/CVD-: 6; SARS-CoV-2- ACEi+: 6; SARS-CoV-2- ARB+: 4; SARS-CoV-2- HT+/CVD±: 10; SARS-CoV-2+ HT-/CVD-: 7; SARS-CoV-2+ ACEi+: 10; SARS-CoV-2+ ARB+: 15; SARS-CoV-2+ HT+/CVD±: 25.

Extended Data Figure 7: Altered immune response in COVID-19 by ACEi/ARB treatment in relation to disease severity.

(a) Dotplot depicts significant gene expression changes of pro-inflammatory mediators, and receptors in rMa, Neu, and NKT of hypertensive patients with (HT+/CVD+, n (SARS-CoV-2-/+) = 4/4) or without an additional CVD (HT+/CVD-, n (SARS-CoV-2-/+) = 6/6) compared to HT-/CVD- patients (n (SARS-CoV-2-/+) = 6/6). Red circles indicate Benjamini-Hochberg adjusted two-tailed negative binomial p -value < 0.05. Samples with no contributing cells per cell type were excluded from analysis. (b) Alterations of gene expression in rMa of hypertensive patients treated either with ARB+ (n (SARS-CoV-2-/+) = 4/15), or ACEi+ (n (SARS-CoV-2-/+) = 6/10) in comparison to HT-/CVD- patients (n (SARS-CoV-2-/+) = 6/6). (c) Significant changes of gene expression in nrMa and Neu obtained from the bronchial lavage of the COVID-19

HT+/CVD+/ARB+ patient (BIH-SCV2-30) and the HT-/CVD- patient (BIH-SCV2-25). (d) Average gene expression of *CCR1* in nrMa and Neu of SARS-CoV-2 negative (n=11 Neu, n=13 nrMa), severe COVID-19 (n=24 Neu/nrMa), and critical COVID-19 (n=9 Neu/nrMa) patients. Mann-Whitney U-test: * p -value<0.05, ** p -value<0.005, *** p -value<0.0005. Ave. Exp. = average expression, Pct. Exp. = percentage of cells expressing the gene. BL = bronchial lavage.